Canaccord Adams
http://www.canaccordadams.com/default.htmCanaccord Adams is a leading independent financial services firm committed to fostering the entrepreneurial economy by bringing corporate and institutional clients unique perspective on global investment opportunities. With operations in research, sales and trading, and investment banking, their 225 professionals seek out emerging opportunities in their key sectors - Mining and Metals, Energy, Technology, Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth. Located in nine offices internationally, their experienced team generates focused, actionable ideas that identify opportunity and facilitate growth.
View Older Stories View More Recent Stories
-
Canaccord Adams Upgrades 3D Systems (TDSC) to Buy; Q4 upside, Visibility Beginning to Improve
-
Canaccord Adams Upgrades St. Mary Land & Exploration (SM) to Buy
-
Canaccord Adams Maintains a 'Buy' on DigitalGlobe (DGI); Q4 Results Mixed
-
SinoHub (SIHI) Enters SPA for 1.37M Common at $3.00/Share
-
Canaccord Adams Lifts Price Target Dendreon (DNDN) to $47
-
Underwriters Exercise Over-Allotment Option in Labopharm (DDSS) 13.53M Common Offering
-
Notable Analyst Rating Changes 02/19: ADBE, SCHW, WBMD, SFI Upgraded; FSLR, ELGX, WIN, AAP Downgraded
-
Canaccord Adams Reiterates a 'Buy' on Swift Energy (SFY); Year Starting With Momentum
-
Canaccord Adams Maintains a 'Buy' on WebMD Health Corp. (WBMD); Continued Momentum From Major Customer Wins
-
Canaccord Adams Maintains a 'Buy' on Wright Medical Group (WMGI); 2010 Guidance Show Continued Stabilization
-
Canaccord Adams Reiterates a 'Buy' on ev3 Inc. (EVVV); Positive on Q4 Results and Guidance
-
Labopharm (DDSS) Closes Offering of 11.76M Units at $1.70/Unit
-
Notable Analyst Rating Changes 02/18: BEAT, CRM, FSLR, NUE Upgrades; XNPT, CSCX, NTAP, THOR Downgraded
-
Canaccord Adams Reiterates a 'Buy' on Inverness Medical Innovations (IMA); Lowers Estimates & PT
-
Canaccord Adams Reiterates a 'Buy' on Orthofix International (OFIX); Raises PT & Estimates
-
Canaccord Adams Reiterates a 'Buy' on NVIDIA (NVDA); Raises PT & Estimates
-
Canaccord Adams Downgrades NetApp (NTAP) to Hold
-
Notable Analyst Rating Changes 02/17: SNDK, HD, WFMI, ABFS Upgraded; VCLK, SNI, PAAS, CHE Downgraded
-
Canaccord Adams Downgrades ValueClick (VCLK) to Hold
-
Canaccord Adams Reiterates a 'Buy' Rating on Motorola (MOT); Positive on Split
-
Canaccord Adams Maintains a 'Buy' on Rovi Corporation (ROVI); Strong Q4 Beat
-
Canaccord Adams Maintains a 'Hold' on Vale (VALE); Lowers PT & Estimates
-
Canaccord Adams Upgrades EnCana (ECA) to Buy; Raises PT & Estimates
-
Labopharm (DDSS) Prices 11.76M Common Offering at $1.70/Unit
-
Canaccord Adams Reiterates a 'Buy' on Insulet Corp (PODD); Raises PT After Q4 Results
-
Canaccord Adams Initiates Coverage on Swift Energy (SFY) with a Buy; Legacy Assets Providing a Launch Pad
-
Canaccord Adams Initiates Coverage on Gastar Exploration (GST) with a Buy; Digging Deep for Returns
-
Canaccord Adams Reiterates a 'Buy' on HeartWare International (HTWR); Adjusts Price Target & Estimates
-
Canaccord Adams Raises Price Target On Labopharm (DDSS) After Oleptro Approval, Partnership Is Next
-
Canaccord Adams Riterates a 'Buy' on Concur Technologies (CNQR); Raises PT
-
Canaccord Adams Maintains a 'Buy' on Motorola (MOT); Reduces Estimates & PT
-
Wall Street's Thoughts On Microsoft (MSFT) After Strong Q4 Driven By Windows 7
-
Wall Street's Thoughts On Apple's (AAPL) iPad
-
Canaccord Adams Maintains a 'Buy' on New Gold Inc. (NGD); Slight Positive on Sale of Amapari Mine
-
Canaccord Adams Reiterates a 'Buy' on Green Mountain Coffee (GMCR); Raises PT & Estimates
-
Canaccord Adams Initiates Coverage on Medicis Pharmaceutical (MRX) with a Buy
-
Canaccord Adams Reiterates a 'Buy' on Intersil (ISIL); Raises PT & Estimates
-
Canaccord Adams Reiterates a 'Buy' on Baker Hughes (BHI); Raises PT
-
Canaccord Adams Maintains a 'Buy' on Yahoo! (YHOO); Raises PT
-
Canaccord Adams Reiterates a 'Buy' on Stryker (SYK); Raises PT
-
Daily State of the Markets 1/27: Guess They're Serious
-
Canaccord Adams Upgrades QLogic (QLGC) to Buy
-
Canaccord Adams Initiates Coverage on Nexxus Lighting (NEXS) with a Buy
-
Analyst Thoughts On Apple (AAPL) After Strong Q1 Results
-
Canaccord Adams Said Novo Approval Is Negative for Amylin (AMLN)
-
Unusual 11 Mid-Day Movers 1/25: SMTX, NBS, KFS, SILC, PVTB Higher; PARD, ZAGG, DEAR, BBX Lower
-
Morning Movers 1/25: SMTX, NBS, ERI, KFS, PVTB, CADC Higher; PARD, SNEN, BBX, PCBC Lower
-
Notable Analyst Rating Changes 01/25: GD, SOLF, DRYS, EGLE, SAP Upgraded; PRSP, PARD, IGT, LPX, TSS Downgraded
-
Canaccord Adams Downgrades Poniard Pharmaceuticals (PARD) to Sell; Slight Picoplatin Underperformance
-
Analyst Thoughts On Google (GOOG) After Solid Q4 Results and Subsequent Sell-Off

